Keyword: Congress

FDA nominee Stephen Hahn faced questions from senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

Nearly 8 in 10 Americans believe drug costs are too high, according to a new poll, and as the elections near, voters will be watching.

Merck CEO Ken Frazier knows the industry is in the political "crosshairs," but he cautioned against policies that could "hurt innovation."

Nancy Pelosi unveiled her much anticipated drug pricing plan, but Mitch McConnell said the Senate wouldn't take up the legislation.

It's official: Pharma faces an aggressive plan for price negotiation on top brands, price-hike rollbacks and more. But does the bill stand a chance?

New data from analysts at SSR show list prices haven't been growing as fast as they were—and the amount payers actually shell out is falling. 

Each week, we'll track notable drug pricing proposals and developments that could affect how drugmakers operate in the U.S. and beyond.

Proposed bill would empower HHS to negotiate top drug prices, set an international index, levy steep fines—in short, devastate pharma's pricing power.

Merck, Novo Holdings and several smaller drug developers are partnering with BIO to spur R&D in the fight against superbugs.

In the heat of the most ferocious battle over drug prices in years, pharmaceutical companies are showering U.S. senators with campaign cash.